Real‐world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database

OBJECTIVE: This study aimed to systematically evaluate and compare the post-marketing safety of four newer antiseizure medications (ASMs)-brivaracetam (BRV), cannabidiol (CBD), cenobamate (CNB), and fenfluramine (FFA). METHODS: A pharmacovigilance study was conducted using data from the FAERS database (Q1 2016-Q4 2024). Disproportionality analyses were performed to detect adverse event (AE) signals using three algorithms. Subgroup analyses were stratified by age, sex, reporter, and treatment strategy. We employed multivariable logistic regression, adjusted for covariates including age, sex, weight, dose, and concomitant medications, to validate associations between ASMs and specific AEs and to identify potential influencing factors. Bayesian network analysis was conducted to explore conditional dependencies among variables. Hospitalization risk was evaluated based on system organ classes. RESULTS: After data cleaning, 13 763 reports were included. We identified 308 positive preferred term (PT) signals. Seizure-related AEs were frequently reported. All four ASMs had the PT of seizure cluster, with each exhibiting distinct AE profiles: BRV with psychiatric disorders, CBD with gastrointestinal events, CNB with visual dysfunction, and FFA with valvular heart disease (VHD). Children had higher reporting odds of seizure with BRV and CBD, while reporting odds of FFA-related VHD were lower in children; polytherapy was associated with higher reporting odds of somnolence, and AE reporting patterns varied by reporter source. Both CBD-related gastrointestinal events and FFA-related cardiac events exhibited dose-dependent effects. Infection-related AEs were associated with higher odds of hospitalization for multiple ASMs. SIGNIFICANCE: This study comprehensively characterizes the safety profiles of newer ASMs and highlights the importance of tailored AE monitoring based on specific ASM and patient characteristics.

Authors

Institutions

Publication Details

Journal
Epileptic Disorders
Published
2026-11-17
DOI
https://doi.org/10.1002/epd2.70479
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‐world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database

Baomin Li, Zimeng He, T Y Li, Fang Fang et al.
6 links
Epileptic Disorders
Pharmacovigilance and Adverse Drug Reactions
article

Real‐world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database

Baomin Li, Zimeng He, T Y Li, Fang Fang, Xiaofan Yang, Minhan Song, Ying Zou, Chaolong Xu, Yang Liu, Yuyan Chang
article en

Abstract

OBJECTIVE: This study aimed to systematically evaluate and compare the post-marketing safety of four newer antiseizure medications (ASMs)-brivaracetam (BRV), cannabidiol (CBD), cenobamate (CNB), and fenfluramine (FFA). METHODS: A pharmacovigilance study was conducted using data from the FAERS database (Q1 2016-Q4 2024). Disproportionality analyses were performed to detect adverse event (AE) signals using three algorithms. Subgroup analyses were stratified by age, sex, reporter, and treatment strategy. We employed multivariable logistic regression, adjusted for covariates including age, sex, weight, dose, and concomitant medications, to validate associations between ASMs and specific AEs and to identify potential influencing factors. Bayesian network analysis was conducted to explore conditional dependencies among variables. Hospitalization risk was evaluated based on system organ classes. RESULTS: After data cleaning, 13 763 reports were included. We identified 308 positive preferred term (PT) signals. Seizure-related AEs were frequently reported. All four ASMs had the PT of seizure cluster, with each exhibiting distinct AE profiles: BRV with psychiatric disorders, CBD with gastrointestinal events, CNB with visual dysfunction, and FFA with valvular heart disease (VHD). Children had higher reporting odds of seizure with BRV and CBD, while reporting odds of FFA-related VHD were lower in children; polytherapy was associated with higher reporting odds of somnolence, and AE reporting patterns varied by reporter source. Both CBD-related gastrointestinal events and FFA-related cardiac events exhibited dose-dependent effects. Infection-related AEs were associated with higher odds of hospitalization for multiple ASMs. SIGNIFICANCE: This study comprehensively characterizes the safety profiles of newer ASMs and highlights the importance of tailored AE monitoring based on specific ASM and patient characteristics.

Epileptic Disorders
Capital Medical University (CN), Beijing Children’s Hospital (CN), Qilu Hospital of Shandong University (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon